In conclusion, our study found that obatoclax, as well as the inhibition of anti-apoptotic Bcl-2 families, exhibited synergistic effects with multiple ER stress inducers, which could be a potential therapeutic strategy for GBM treatment. The gene discussed is BCL2; the disease is glioblastoma.